SCOTTSDALE, Ariz., June 07, 2018 (GLOBE NEWSWIRE) -- Hope Pharmaceuticals today announced that the company filed a Supplemental New Drug Application to the United States Food and Drug Administration (FDA) for the use of Sodium Thiosulfate Injection to prevent a potential complication associated with the administration of a chemotherapeutic agent. 

Image of Hope Pharmaceuticals' FDA-Approved Sodium Thiosulfate Injection that is currently distributed in the United States.

Hope Pharmaceuticals’ Sodium Thiosulfate Injection has already been approved by the FDA as an antidote for acute cyanide poisoning that is judged to be life-threatening and is currently distributed in the United States in individually-packaged 50 mL vials. 

Additional information about Sodium Thiosulfate Injection is available online at www.thiosulfate.info.

Hope Pharmaceuticals is a privately owned company located in Scottsdale, Arizona. 

Media Inquiries:                     
Craig Sherman, M.D. 
(480) 607-1970 or questions@hopepharm.com 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/46d06ce3-2c6d-4331-b241-780a196d92c5

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.